
InflaRx, a bm|t Investee-Partner, completed a minimum 75 Mio. USD equity raise, greatly enhancing the company’s ability to continue advancing its promising pipeline through multiple significant milestones.
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public